Expertise in
14
conditions

Dr. Ashiq M. Masood

Oncology
Univ. Radiation Oncology Associates Inc.
535 Barnhill Dr, 
Indianapolis, IN 
Accepting New Patients
Expertise in
14
conditions
Univ. Radiation Oncology Associates Inc.
535 Barnhill Dr, 
Indianapolis, IN 

Overview

Ashiq Masood is an Oncologist practicing medicine in Indianapolis, Indiana.

Dr. Masood is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Pancreatic Cancer, Colorectal Cancer, Familial Pancreatic Cancer, Neuroendocrine Tumor, and Tissue Biopsy.

He is actively involved in clinical research, co-authoring 43 peer reviewed articles and participating in 9 clinical trials. Dr. Masood is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in IN

Hospital Affiliations

Indiana University Health Bloomington Hospital
Indiana University Health
Indiana University Health Ball Memorial Hospital
Indiana University Health Arnett Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Health Services
  • EPO
  • MANAGED MEDICAID PLAN
  • OTHER COMMERCIAL
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

Univ. Radiation Oncology Associates Inc.
535 Barnhill Dr, Indianapolis, IN 46202
Other Locations
Indiana University Health West Hospital
1111 Ronald Reagan Pkwy, Avon, IN 46123

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients With Resected Head of Pancreas Adenocarcinoma
A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients With Resected Head of Pancreas Adenocarcinoma
Enrollment Status: Completed
Publish Date: February 23, 2026
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Capecitabine, Chemotherapy, Erlotinib hydrochloride, Fluorouracil, Gemcitabine hydrochloride
Study Phase: Phase 3
Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma
Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma
Enrollment Status: Completed
Publish Date: January 21, 2026
Intervention Type: Drug, Device
Study Drugs: Gemcitabine, Nab-paclitaxel
Study Phase: Phase 3
An Open-label Window of Opportunity Trial to Evaluate the Activity of Durvalumab (MEDI4736) and Tremelimumab With Platinum-based Chemotherapy (Gemcitabine and Cisplatin) in Intrahepatic Cholangiocarcinoma (ICC)
An Open-label Window of Opportunity Trial to Evaluate the Activity of Durvalumab (MEDI4736) and Tremelimumab With Platinum-based Chemotherapy (Gemcitabine and Cisplatin) in Intrahepatic Cholangiocarcinoma (ICC)
Enrollment Status: Terminated
Publish Date: November 05, 2024
Intervention Type: Drug
Study Drug: Chemotherapy+Immunotherapy
Study Phase: Phase 1/Phase 2
A Phase 1, Open-label, Dose-escalation Study of SEA-CD40 in Adult Patients With Advanced Malignancies
A Phase 1, Open-label, Dose-escalation Study of SEA-CD40 in Adult Patients With Advanced Malignancies
Enrollment Status: Terminated
Publish Date: May 01, 2023
Intervention Type: Drug
Study Drugs: SEA-CD40, Pembrolizumab, Gemcitabine, Nab-Paclitaxel
Study Phase: Phase 1
DRAGON 1- Training, Accreditation, Implementation and Safety Evaluation of Portal and Hepatic Vein Embolization to Accelerate Future Liver Remnant (FLR) Hypertrophy
DRAGON 1- Training, Accreditation, Implementation and Safety Evaluation of Portal and Hepatic Vein Embolization to Accelerate Future Liver Remnant (FLR) Hypertrophy
Enrollment Status: Unknown
Publish Date: February 03, 2023
Intervention Type: Procedure
Study Phase: Not Applicable
Phase Ib Study of BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer
Phase Ib Study of BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer
Enrollment Status: Terminated
Publish Date: April 21, 2021
Intervention Type: Drug, Procedure
Study Phase: Phase 1
Genomic Landscape of EGFR Mutant NSCLC Prior to Erlotinib and at the Time of Disease Progression Following Erlotinib
Genomic Landscape of EGFR Mutant NSCLC Prior to Erlotinib and at the Time of Disease Progression Following Erlotinib
Enrollment Status: Terminated
Publish Date: July 18, 2019
A Phase II Study of MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors
A Phase II Study of MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors
Enrollment Status: Terminated
Publish Date: November 06, 2018
Intervention Type: Drug
Study Phase: Phase 2
A Phase I/II Study of Pacritinib in Patients With EGFR Mutant NSCLC After EGFR TKI
A Phase I/II Study of Pacritinib in Patients With EGFR Mutant NSCLC After EGFR TKI
Enrollment Status: Terminated
Publish Date: February 27, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 8 Less Clinical Trials

43 Total Publications

ProAgio, a Novel Integrin αvβ3 Targeted Cytotoxin, Suppresses Tumor Growth and Reprograms the PDAC Microenvironment.
ProAgio, a Novel Integrin αvβ3 Targeted Cytotoxin, Suppresses Tumor Growth and Reprograms the PDAC Microenvironment.
Journal: bioRxiv : the preprint server for biology
Published: February 06, 2026
Similar Doctors
Expertise in
20
conditions
Expertise in
20
conditions
Referral may be required

Indiana University Health University Hospital

550 University Blvd, 
Indianapolis, IN 
 (0.1 miles away)
317-944-5000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Lawrence Einhorn is an Oncologist practicing medicine in Indianapolis, Indiana. Dr. Einhorn is highly rated in 20 conditions, according to our data. His clinical expertise encompasses Testicular Cancer, Teratoma of the Mediastinum, Testicular Yolk Sac Tumor, Mediastinal Tumor, and Orchiectomy. Dr. Einhorn is currently accepting new patients.

Expertise in
19
conditions
Expertise in
19
conditions
Referral may be required

Univ. Radiation Oncology Associates Inc.

535 Barnhill Dr, 
Indianapolis, IN 
 (0.1 miles away)
317-944-0920
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Nasser Hanna is an Oncologist practicing medicine in Indianapolis, Indiana. Dr. Hanna is highly rated in 19 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Testicular Cancer, Teratoma of the Mediastinum, and Orchiectomy. Dr. Hanna is currently accepting new patients.

Expertise in
14
conditions
Dr. Brian D. Weiss
Hematology | Oncology
Expertise in
14
conditions
Dr. Brian D. Weiss
Hematology | Oncology
Referral may be required

Riley Hospital For Children At Indiana University Health

705 Riley Hospital Dr, 
Indianapolis, IN 
 (0.2 miles away)
317-944-2143
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Brian Weiss is a Hematologist and an Oncologist practicing medicine in Indianapolis, Indiana. Dr. Weiss is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, Neurofibromatosis, Lithotripsy, and Bone Marrow Transplant. Dr. Weiss is currently accepting new patients.

Frequently Asked Questions about Dr. Ashiq M. Masood

How do I make an appointment with Dr. Ashiq M. Masood?

You can book an appointment with Dr. Ashiq M. Masood by calling their office at 317-944-0920. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Ashiq M. Masood a top-rated expert for Pancreatic Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Ashiq M. Masood is classified as an Distinguished expert for Pancreatic Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Ashiq M. Masood specialize in?

While Dr. Ashiq M. Masood is a Oncology, they have specific expertise in Pancreatic Cancer, Colorectal Cancer, and Familial Pancreatic Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Ashiq M. Masood participate in research or clinical trials?

Yes. Dr. Ashiq M. Masood has published 43 articles and abstracts on conditions like Pancreatic Cancer. You can view a list of Dr. Ashiq M. Masood's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Ashiq M. Masood accept my insurance?

Dr. Ashiq M. Masood accepts most major insurance plans, including Anthem BCBS and Blue Cross Blue Shield. We recommend calling the office directly at 317-944-0920 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Masood's expertise for a condition
ConditionClose
    View All 11 Advanced Conditions
    View All 59 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile